Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.

Oncotarget - 25 Apr 2017

Gottlieb Aline, Althoff Kristina, Grunewald Laura, Thor Theresa, Odersky Andrea, Schulte Marc, Deubzer Hedwig E, Heukamp Lukas, Eggert Angelika, Schramm Alexander, Schulte Johannes H, Künkele Annette

Abstract excerpt

Current therapy of medulloblastoma, the most common malignant brain tumor of childhood, achieves 40-70% survival. Secondary chemotherapy resistance contributes to treatment failure, where TP53 pathway dysfunction plays a key role. MDM2 interaction with TP53 leads to its degradation. Reactivating TP53 functionality using small-molecule inhibitors, such as RITA, to disrupt TP53-MDM2 binding may have therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cerebellar Neoplasms
Share to Cyclin-Dependent Kinase Inhibitor p21

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Furans

Share to Kaplan-Meier Estimate

Share to Medulloblastoma

Share to Mice, Nude

Share to Proto-Oncogene Proteins c-mdm2

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 28427187
DOI: 10.18632/oncotarget.15840
PMCID: PMC5438615

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.PMID 28427187Read ↗

Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.Semantic proximity Read ↗

Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.Semantic proximity Read ↗

Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumorsSemantic proximity Read ↗

Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomideSemantic proximity Read ↗

Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA.Semantic proximity Read ↗

Targeting the p53 pathway to treat Malignant Rhabdoid and Atypical Teratoid Rhabdoid TumorsSemantic proximity Read ↗

Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma.Semantic proximity Read ↗

Antitumor Activities and Cellular Changes Induced by TrkB Inhibition in MedulloblastomaSemantic proximity Read ↗

RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic ResponsesSemantic proximity Read ↗

Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.Semantic proximity Read ↗

Mir-34a mimics are potential therapeutic agents for p53-mutated and chemo-resistant brain tumour cells.Semantic proximity Read ↗

RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.